Fig. 3

Effect of glepaglutide co-treatment or post-treatment on small intestinal length in the active inflammation phase. Effect of a co-treatment or post-treatment regimen of glepaglutide (400 nmol/kg, SC, twice daily) on small intestinal length (cm) was assessed in the active inflammation phase (2–3 days after inflammation onset), in Wistar rats with small intestinal inflammation. ***p < 0.001 vs INDO controls. Data shown are mean ± SEM. INDO, indomethacin; SC, subcutaneously; SEM, standard error of the mean